Search clinical trials for: CD5024

Total 43 results

Galderma R&D

Completed

Efficacy and Safety of CD5024 1% in Acne Vulgaris

Acne

France, Canada, Germany
Galderma R&D

Completed

Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis

Atopic Dermatitis

Canada
Galderma R&D

Completed

Phase 3 Papulopustular Rosacea Study

Papulopustular Rosacea

United States, Canada
Galderma R&D

Completed

Phase 3 Papulopustular Rosacea Study

Papulopustular Rosacea (PPR)

United States, Canada
Adiso Therapeutics

Completed

A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)

Clostridium Difficile Infection Recurrence

United States, Canada
Apnimed

Completed

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

Obstructive Sleep Apnea

United States
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-5024 Safety and PK in Healthy Adult Volunteers

Healthy Subjects

Netherlands
Galderma R&D

Completed

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Tel-Aviv Sourasky Medical Center

Recruiting

Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection

SARS-CoV-2

Israel
Athens Medical Society
Elpen Pharmaceutical Co. Inc.; OBCTCD24 Ltd

Recruiting

Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19

Covid19

Greece
Nano24med

Recruiting

Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS

ARDS

Israel
Amina Fouad Farag

Completed

Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland Tumours

Carcinoma Ex Pleomorphic Adenoma of Salivary Glands | Pleomorphic Adenoma of Salivary Glands

Egypt
Eli Sprecher, MD
OBCTCD24 Ltd

Active, not recruiting

A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection

COVID-19 Disease

Israel
Northwestern University
GlaxoSmithKline; National Comprehensive Cancer Network

Active, not recruiting

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Sweden
Galderma R&D

Completed

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. (MOSAIC)

Rosacea

United States, Canada
Lanzhou Institute of Biological Products Co., Ltd

Recruiting

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell

China
Case Comprehensive Cancer Center
Cephalon

Terminated

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Mayo Clinic

Completed

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphocytic Leukemia

United States
Tianhong Li
National Cancer Institute (NCI); OncoImmune, Inc.

Terminated

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

Advanced Malignant Solid Neoplasm

United States
Shanghai Zhangjiang Biotechnology Limited Company

Suspended

Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia (CLL004)

B-cell Chronic Lymphocytic Leukemia

China
OncoImmune, Inc.

Completed

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) (SAC-COVID)

Coronavirus Disease 2019 (COVID-19)

United States
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers

Healthy Subjects

Netherlands
Apnimed

Completed

Parallel Arm Trial of AD109 and AD504 In Patients With OSA (MARIPOSA)

OSA - Obstructive Sleep Apnea

United States
National Cancer Institute (NCI)

Completed

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Galderma R&D

Completed

A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis

Chronic Plaque Psoriasis

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia

United States
Genmab
BioNTech SE

Recruiting

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Malignant Solid Tumor

Japan
OncoImmune, Inc.
University of Maryland, Baltimore

Terminated

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003) (CALIBER)

HIV Infections | Dyslipidemias

United States
National Cancer Institute (NCI)

Completed

Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia

United States
Johns Hopkins University

Recruiting

Human Penile Allotransplantation

Wounds and Injuries | Amputation | Amputation, Traumatic | Urologic Surgical Procedures, Male | Amputation, Traumatic/Surgery | Penis/Transplantation | Penis/Surgery | Penis/Injuries

United States
Wake Forest University Health Sciences

Withdrawn

Human Penile Tissue Allotransplantation for Devastating Penile and Concomitant Genital Trauma

Amputation | Urologic Injuries | Genital Diseases, Male
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States, Italy
OncoImmune, Inc.
National Cancer Institute (NCI); Huntsman Cancer Institute

Withdrawn

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI)

Metastatic Melanoma

United States
University of Göttingen
Nordic Lymphoma Group; German High-Grade Non-Hodgkin's Lymphoma Study Group

Unknown

Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP (A-CHOP-14)

Extranodal NK/T-cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Angioimmunoblastic Lymphadenopathy

Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell... and other conditions

United States, Italy
M.D. Anderson Cancer Center

Active, not recruiting

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Recurrent T-Cell Prolymphocytic Leukemia | T-Cell Prolymphocytic Leukemia

United States
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Hematologic Malignancy

United States
Oncoimmune, Inc., a subsidiary of Merck & Co.,...
National Cancer Institute (NCI); University of Michigan Rogel Cancer Center; Ohio... and other collaborators

Completed

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

Leukemia | Hematopoietic Stem Cell Transplantation | Graft Versus Host Disease

United States
OncoImmune, Inc.

Terminated

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) (CATHY)

Acute Graft Versus Host Disease | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Hematopoietic Stem Cell Transplantation

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Sickle Cell Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Immunodeficiency Syndrome | Non-Cancer Diagnosis

United States
National Cancer Institute (NCI)

Completed

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States

Search clinical trials for: CD5024

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations